Breaking News Instant updates and real-time market news.

NVS

Novartis

$71.77

0.26 (0.36%)

18:05
12/22/16
12/22
18:05
12/22/16
18:05

Novartis' Alcon receives FDA approval for AcrySof IQ ReSTOR

Alcon, a division of Novartis, has received approval from the US Food and Drug Administration for its AcrySof IQ ReSTOR +3.0D Multifocal Toric Intraocular Lens. The new IOL is designed to address presbyopia and pre-existing corneal astigmatism at the time of cataract surgery in adult patients who desire good near, intermediate and distance vision with an increased potential for spectacle independence. The product is already commercially available in the European Union, Australia, Canada, and many countries in Central and South America and Asia. "The AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL is an important addition to our market-leading IOL portfolio, and broadens our offering of presbyopia- and astigmatism-correcting lenses to meet the different visual needs of patients," said Sergio Duplan, Alcon Region President for North America. "We are committed to delivering ongoing innovation that enables surgeons to provide the best possible outcome for their patients."

  • 19

    Jan

  • 01

    Feb

  • 21

    Feb

NVS Novartis
$71.77

0.26 (0.36%)

12/19/16
MAXM
12/19/16
NO CHANGE
Target $43
MAXM
Buy
Drop outs of Neulasta competitors may benefit Coherus in EU, says Maxim
Maxim analyst Jason McCarthy noted that Gedeon Richter and STADA Arzneimittel AG have withdrawn their respective MAAs for biosimilar Neulasta, which he said may put Coherus Biosciences in a good position in terms of the competitive landscape for the drug in Europe. Novartis (NVS) and Mylan (MYL) had filed before Coherus and Apotex may file in 2017, noted McCarthy. In the U.S., Novartis' BLA was rejected by the FDA and Coherus could have a two-year head start in commercialization of biosimilar Neulasta, added the analyst, who has a Buy rating and $43 price target on Coherus shares.
12/20/16
HCWC
12/20/16
NO CHANGE
Target $18
HCWC
Buy
Conatus price target doubled to $18 after Novartis pact at H.C. Wainwright
H.C. Wainwright analyst Ed Arce called Conatus' (CNAT) license and collaboration agreement with Novartis (NVS) a "transformational" deal that he believes ends any uncertainty about whether sufficient financial resources exist to support emricasan's full development. The analyst, who is positive on the deal both strategically and financially and predicted shares Conatus will trade up "at least 100% today," raised his price target on the stock to $18 from $9 and affirmed his Buy rating.
12/20/16
STFL
12/20/16
NO CHANGE
STFL
Conatus price target raised to $7 from $5 at Stifel
Stifel analyst Stephen Willey says that Novartis' (NVS) decision to collaborate with Conatus (CNAT) on its emricasan treatment marks a positive turning point for Conatus. Willey notes that the deal provides Conatus with funding and the opportunity to "pursue combination development with Novartis' FXR agonist LJN452," which he believes has synergies with emricasan. The analyst keeps a Buy rating on Conatus.
12/20/16
RHCO
12/20/16
NO CHANGE
RHCO
Conatus price target raised to $26 from $17 at SunTrust
After Conatus (CNAT) announced a partnership deal with Novartis (NVS), SunTrust analyst John Boris says the deal is "transformational" for Conatus. The analyst thinks that the deal will be worth about $1B to Conatus. He believes that the deal makes strategic sense to Conatus because of the potential synergies in the mechanism of action between its NASH treatment and that of Novartis (NVS). Boris keeps a Buy rating on Conatus.

TODAY'S FREE FLY STORIES

08:50
11/20/17
11/20
08:50
11/20/17
08:50
General news
U.S. equities are trading moderately firmer »

U.S. equities are trading…

ACOR

Acorda Therapeutics

$17.80

0.55 (3.19%)

08:49
11/20/17
11/20
08:49
11/20/17
08:49
Technical Analysis
Technical View: Acorda Therapeutics down on end of tozadenant development »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:46
11/20/17
11/20
08:46
11/20/17
08:46
Recommendations
Coca-Cola analyst commentary  »

Coca-Cola investor day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$40.82

8.97 (28.16%)

08:45
11/20/17
11/20
08:45
11/20/17
08:45
Recommendations
Foot Locker analyst commentary  »

Foot Locker price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:45
11/20/17
11/20
08:45
11/20/17
08:45
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

JNJ

Johnson & Johnson

$138.00

-0.87 (-0.63%)

08:43
11/20/17
11/20
08:43
11/20/17
08:43
Hot Stocks
EU extends license for Janssen's Zytiga plus prednisone »

Janssen-Cilag…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

LIVN

LivaNova

$84.32

0.04 (0.05%)

08:42
11/20/17
11/20
08:42
11/20/17
08:42
Recommendations
LivaNova analyst commentary  »

LivaNova received fair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 01

    Dec

MNST

Monster Beverage

$62.17

0.17 (0.27%)

, KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Downgrade
Monster Beverage, Coca-Cola rating change  »

Monster Beverage…

MNST

Monster Beverage

$62.17

0.17 (0.27%)

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NQ

NQ Mobile

$4.05

-0.05 (-1.22%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Hot Stocks
NQ Mobile provides update on FL Mobile Divestment »

NQ Mobile provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENSG

Ensign Group

$23.77

0.22 (0.93%)

08:38
11/20/17
11/20
08:38
11/20/17
08:38
Recommendations
Ensign Group analyst commentary  »

Ensign Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

08:37
11/20/17
11/20
08:37
11/20/17
08:37
Hot Stocks
Marvell: Cavium deal doesn't include divestitures, changes to Cavium's portfolio »

On the conference call…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

BKS

Barnes & Noble

$7.45

0.35 (4.93%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Hot Stocks
Barnes & Noble announces Black Friday weekend deals »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

ARAY

Accuray

$4.80

-0.1 (-2.04%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Technical Analysis
Technical View: Accuray rallies in pre-market »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$2.88

0.02 (0.70%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Hot Stocks
Genius Brands signs multiple content sales deals for children's programming »

Genius Brands expands the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$34.95

-0.33 (-0.94%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Initiation
Aimmune initiated  »

Aimmune initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

WOR

Worthington

$40.24

0.03 (0.07%)

08:33
11/20/17
11/20
08:33
11/20/17
08:33
Hot Stocks
WAVE to sell EMEA, Pacific Rim units »

Worthington (WOR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIV

On Track Innovations

$1.13

-0.01 (-0.88%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
On Track Innovations: UNO 6 selected by CityEV as cashless payment solution »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDSO

Medidata

$68.64

-0.85 (-1.22%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
Medidata, MEL MEDICAL announce multi-year Medidata eTMF agreement »

Medidata announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PNTR

Pointer Telocation

$17.55

-0.2 (-1.13%)

08:30
11/20/17
11/20
08:30
11/20/17
08:30
Downgrade
Pointer Telocation rating change  »

Pointer Telocation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$20.50

0.04 (0.20%)

08:29
11/20/17
11/20
08:29
11/20/17
08:29
Recommendations
Beazer Homes analyst commentary  »

Beazer Homes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Conference/Events
The Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

DG

Dollar General

$85.50

0.59 (0.69%)

, DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Recommendations
Dollar General, Dollar Tree analyst commentary  »

Dollar General price…

DG

Dollar General

$85.50

0.59 (0.69%)

DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

OMI

Owens & Minor

$19.14

0.23 (1.22%)

08:27
11/20/17
11/20
08:27
11/20/17
08:27
Recommendations
Owens & Minor analyst commentary  »

Owens & Minor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIZZ

National Beverage

$102.23

0.32 (0.31%)

08:26
11/20/17
11/20
08:26
11/20/17
08:26
Upgrade
National Beverage rating change  »

National Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.61

-0.86 (-0.91%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
AbbVie analyst commentary  »

AbbVie estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.